Payer’s Place: Dawn Maroney, Alignment Health
CEO of Alignment Health joins the Payer's Place and details how the growth of Medicare Advantage will only help patients in the future.
CEO of Alignment Health joins the Payer's Place and details how the growth of Medicare Advantage will only help patients in the future.
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Pharmaceutical industry observers say CVS Health’s creation of Cordavis, a new biosimilar drugs company, is part of a strategy to make its move into this market as profitable as possible.
The CEO of Providence Health Plan visits the Payer's Place and addresses the future of payment models.
Amgen and the Federal Trade Commission are settling the lawsuit the regulator filed to block the pharmaceutical giant’s $28 billion Horizon Therapeutics acquisition. As part of the settlement, Amgen agrees not to “bundle” its products with Horizon’s drugs in negotiations with health plans.
Carrie Kincaid, Senior Vice President, Market Development at Priority Health discusses how Priority Health is addressing the gaps in rural healthcare.
Peter Long of Blue Shield of California discusses how they focus on member experience and ways to improve their overall healthcare needs.
We need a streamlined approach where stakeholders can perform all critical tasks — from enrollment and patient consent to prior authorization, from real-time benefit checks to financial assistance — on a central platform powered by a business rules engine, automated workflows, and real-time analytics.
OptumRx's Chief Clinical Officer shares his insights on the latest developments and trends he's seen in the healthcare industry.
Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The series, part of a content partnership between HLTH and MedCity News, will share insights from executives from both public and private payer organizations based on developments and trends they've seen in the healthcare industry and what keeps them up at night.
Medicare will cover Alzheimer’s disease drugs granted traditional FDA approval, CMS announced. But the decision keeps the spirit of an earlier coverage determination, which called for the gathering of more evidence about the safety and efficacy of these therapies.
A panel during the MedCity News INVEST conference discussed what digital health technologies need to do to demonstrate return on investment for payers, providers, and other stakeholders.
Pear Therapeutics’ Chapter 11 bankruptcy filing follows three corporate restructurings and the inability to secure additional financing to support commercialization of its FDA-cleared prescription digital therapeutics. An auction of Pear’s assets is expected to happen in early May.